ABROGATE |
Abatacept (CTLA-4 immunoglobulin) |
Not yet recruiting |
GPA |
Treatment failure after 12 months of treatment |
NCT02108860 |
Evaluate the efficacy of achieving glucocorticoid-free remission in patients with relapsing non-severe GPA |
ALEVIATE |
Alemtuzumab (monoclonal anti-CD52) |
Unknown |
GPA and MPA |
Complete or partial remission after 6 months; adverse event |
NCT01405807 |
Evaluating whether alemtuzumab induces sustained remission in refractory patients |
BIANCA-SC |
Blisibimod (selective antagonist of BAFF) |
Not yet recruiting |
GPA and MPA |
Induction of clinical remission |
NCT01598857 |
Evaluate efficacy of blisibimod when taken with methotrexate to induce remission |
BREVAS |
Belimumab (human monoclonal anti-BAFF) |
Recruiting |
GPA and MPA |
Time to first relapse |
NCT01663623 |
Assessing efficacy of belimumab in maintenance of remission following a standard induction regimen |
CLASSIC |
CCX168 (C5a inhibitor) |
Recruiting |
GPA and MPA |
Safety and efficacy of two-dose regimen |
NCT02222155 |
Studying the safety and efficacy of CCX168 for induction therapy (low versus high dose) with conventional therapy |
CLEAR |
CCX168 (C5a inhibitor) |
Recruiting |
GPA and MPA |
Safety (adverse events) and efficacy (BVAS) |
NCT01363388 |
Studying the safety and efficacy of CCX168 versus placebo for induction therapy on a background of conventional therapy |
LoVAS |
Rituximab with glucocorticoids |
Recruiting |
GPA and MPA |
Remission induction |
NCT02198248 |
Comparing rituximab with low-dose glucocorticoids versus rituximab with high-dose glucocorticoids |
MAINRITSAN-2 |
Rituximab (two strategies) |
Active, not recruiting |
GPA and MPA |
Number of minor and major relapses |
NCT01731561 |
Assess efficacy of a rituximab regimen based on rate of ANCA and CD19 lymphocytes for maintenance of remission |
PEXIVAS |
Plasma exchange |
Recruiting |
GPA and MPA |
All-cause mortality; end-stage renal disease |
NCT00987389 |
Determining whether plasma exchange with immunosuppressive therapy are effective in reducing death and ESRD |
RAVELOS |
Rituximab (chimeric monoclonal anti-CD20) |
Recruiting by invitation |
GPA and MPA |
Long-term safety and effects of rituximab |
NCT01586858 |
Following the patients included in the RAVE study to study long-term outcome after rituximab treatment |
RITAZAREM |
Rituximab |
Recruiting |
GPA and MPA |
Time to first relapse |
NCT01697267 |
Evaluating whether repeated rituximab will maintain remission |
SCOUT |
Glucocorticoids and rituximab |
Recruiting |
GPA and MPA |
Complete remission |
NCT02169219 |
Studying whether an 8-week course of glucocorticoids with rituximab is effective as remission induction |
TAPIR |
Glucocorticoids |
Recruiting |
GPA |
Increase of the glucocorticoid dose for disease relapse |
NCT01933724–NCT01940094
|
Evaluating the effects of low-dose glucocorticoids (5 mg/day) versus stopping completely in GPA in remission |